Darmiyan

Darmiyan is a medical AI company whose product, BrainSee, analyzes standard clinical brain MRI scans to detect and quantify early neurodegeneration. The software examines the tissue architecture within every voxel of a scan, focusing on the space between brain cells, to find cellular level changes that a conventional read does not reveal. Its first application is Alzheimer's disease: for patients with mild cognitive impairment it produces degeneration maps showing focal areas of change and a five year prognosis for conversion to Alzheimer's dementia. It is intended for physicians evaluating patients with early memory complaints, for pharmaceutical companies developing Alzheimer's treatments, and for clinical researchers who need a non invasive, objective measure of brain health from imaging the patient already has. The company positions it as a way to identify disease at the stage where interventions matter most. BrainSee holds FDA Breakthrough Device designation and received FDA De Novo authorization, and the company cites third party validation by independent investigators in the United States and Canada. Eisai is among its investors. Pricing is not published. BrainSee is sold to healthcare providers and pharmaceutical partners rather than directly to patients, and access is arranged with the company. Buyers should note that this is regulated clinical software with a single indication today; it is not a general purpose imaging analysis platform.